T-2543-22: Court Orders Inventorship Correction on Two PNH Complement Inhibitor Patents
The Canadian Federal Court granted an application to add Mark J. Evans as a named inventor on CA2645810 and CA3022097, both covering treatment of paroxysmal nocturnal hemoglobinuria by a complement inhibitor. The court allowed the application in full, correcting the inventorship record on both granted Canadian patents.
Canadian Court Corrects Inventorship on Two Key PNH Biologics Patents
On 24 January 2023, Justice Michael D. Manson of the Canadian Federal Court granted an application in case T-2543-22 to add Mark J. Evans as a named inventor on two granted Canadian patents: CA2645810 and CA3022097. Both patents relate to the treatment of paroxysmal nocturnal hemoglobinuria (PNH) using a complement inhibitor — a clinically significant biologic drug class. Plaintiff and defendant details are not disclosed in the available record.
The recorded basis of termination is 'Case Accepted,' signifying the court accepted the application on its merits and entered judgment accordingly. The court's order is unambiguous: Evans is to be added as an inventor to both patents. The specific factual basis on which the court found inventorship — including what contribution Evans was found to have made — is not detailed in the available public record beyond the judgment text.
Inventorship correction proceedings under Canadian patent law are procedurally distinct from infringement actions and are resolved relatively quickly when the evidentiary record is clear. The speed of resolution here is consistent with an uncontested or lightly contested application, though whether any party opposed the application is not disclosed in the available record. The commercial significance of the correction lies in the patents themselves: complement inhibitor therapies for PNH represent a high-value biologics segment.
See Complete Case & Patent Analysis →Filing to Case Accepted in 0 days
Case closed 24 January 2023; filing date not recorded in the available docket data
CA2645810 & CA3022097 — PNH Treatment by Complement Inhibitor
Any R&D team or product organisation developing complement inhibitor therapies for PNH or related complement-mediated disorders with Canadian market ambitions should assess freedom to operate against CA2645810 and CA3022097. These are granted Canadian patents in a high-enforcement rare disease segment, and the inventorship record has now been judicially confirmed — reducing one traditional challenge pathway available to potential infringers.
Official order — verbatim text
The judgment text is unambiguous: Justice Manson granted the application in full, ordering Evans added as inventor to both CA2645810 and CA3022097. The ruling reflects a merits-based acceptance of the inventorship claim rather than a procedural or consent resolution. The specific evidentiary findings underlying the court's determination are not reproduced in the available record.
Application granted: what the inventorship correction means for both patents
Inventorship correction: a court-ordered amendment to the patent record
Under Canadian patent law, a court may order the correction of inventorship on a granted patent where the named inventors do not accurately reflect those who contributed to the invention. Here, the court found the application meritorious and ordered Evans added to both CA2645810 and CA3022097. The correction is entered into the official patent register and is binding going forward.
Inventorship corrected by court orderEvans formally recognised as co-inventor on both PNH patents
The judgment establishes Mark J. Evans as a named inventor on both granted Canadian patents. This has direct legal consequences: inventorship is a matter of patent validity and ownership entitlement in Canada. Recognition as an inventor can affect rights to ownership, licensing proceeds, and the validity of any subsequent assignments or licences tied to the patents. The specific downstream commercial arrangements, if any, are not disclosed in the available record.
Inventor status formally establishedExisting patent ownership and licences may require re-evaluation
Where inventorship on a granted patent is corrected by court order, parties holding licences, assignments, or commercialisation rights derived from the original patent record should assess whether those arrangements remain valid and complete under Canadian law. Whether any such third-party interests exist in relation to CA2645810 or CA3022097 is not disclosed in the available record.
Ownership and licence review warrantedPNH complement inhibitor IP landscape now has a corrected inventorship record
CA2645810 and CA3022097 sit in one of the highest-value rare disease biologics segments. Complement inhibitor therapies for PNH command significant commercial revenues globally. A judicially corrected inventorship record on these patents may have implications for licensing strategy, co-ownership arrangements, and any future validity challenges — since inventorship errors can be raised as grounds of invalidity in Canadian proceedings.
High-value rare disease biologics segmentFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Plaintiff | Individual | Applicant seeking inventorship correction — holder or associated party of CA2645810 and CA3022097Search in Eureka ↗ |
| Defendant | Defendant | Individual | Respondent party details not disclosed in the available docket recordSearch in Eureka ↗ |
| Presiding judge | Judge Michael D. Manson | Judge | Canada Federal courtSearch in Eureka ↗ |
R&D signals in the complement inhibitor and PNH patent space
Forward-looking patent and innovation intelligence on complement inhibitor biologics, PNH treatment IP, and the Canadian rare disease patent landscape implicated by this case.
Complement inhibitor patent filings: who is building coverage in Canada?
CA2645810 and CA3022097 sit within a competitive complement inhibitor filing landscape. Tracking which organisations are actively prosecuting complement pathway patents in Canada — including C5, C3, and factor D inhibitors — signals where the next enforcement or licensing flashpoints are likely to emerge in the PNH and broader complement-mediated disease space.
Complement inhibitor filing trendsNext-generation PNH therapy patents: where is the field moving?
Beyond C5 inhibition — the mechanism historically associated with leading PNH therapies — patent activity is accelerating in upstream complement pathway targets, oral small-molecule inhibitors, and long-acting biologics. Monitoring filing trends in these adjacent spaces helps R&D teams identify white space and anticipate competitor IP positioning before market entry.
PNH next-gen therapy IPHow are PNH biologics competitors positioning their Canadian patent estates?
The judicial correction of inventorship on CA2645810 and CA3022097 draws attention to the broader Canadian patent strategies of complement inhibitor developers. Analysing the Canadian prosecution history, divisional filings, and continuation activity of key players in this space reveals where exclusivity is being extended and where challenges may be viable.
Canadian biologics competitive IPUnprotected approaches in complement-mediated rare disease: where is the gap?
Despite dense patenting around established PNH complement targets, patent mapping typically reveals white space in delivery mechanism innovation, combination therapy claims, and patient subpopulation-specific dosing regimens. R&D teams entering or expanding in the complement inhibitor space should map these gaps before committing to late-stage development pathways.
Complement IP white spaceSimilar Canadian Federal Court inventorship and biologics patent cases
Explore related Canadian Federal Court proceedings involving inventorship correction, complement inhibitor patents, and rare disease biologics IP disputes.
What this case signals for biologics patent inventorship in Canada
Inventorship disputes on high-value biologics patents are a growing litigation vector. This ruling is a reminder that the Canadian Federal Court will intervene to correct the record.
Inventorship errors on biologics patents carry real commercial risk in Canada
Canadian courts will correct inventorship on granted patents where the evidentiary record supports it. For companies holding biologics patents with complex, multi-contributor research histories — common in PNH and complement inhibitor development — an uncorrected inventorship record is a potential validity risk in future proceedings.
Complement inhibitor patents are a high-priority FTO and validity monitoring target
CA2645810 and CA3022097 now carry a corrected inventorship record following a Federal Court order. Any party with Canadian market exposure in the PNH or complement inhibitor space should ensure their freedom-to-operate and validity analysis reflects the current state of both patents, including the updated inventor register.
Plaintiff v Defendant — key questions answered
Justice Manson of the Canadian Federal Court granted the application in full, ordering that Mark J. Evans be added as a named inventor on both CA2645810 and CA3022097. Both patents relate to treatment of paroxysmal nocturnal hemoglobinuria by a complement inhibitor. The judgment was entered on 24 January 2023.
A court-ordered inventorship correction amends the official patent register. In Canada, inventorship is tied to ownership entitlement and affects the validity of assignments and licences executed under the prior record. Parties holding rights derived from the patents before correction should assess whether their arrangements remain complete and valid under the corrected inventorship.
Inventorship errors can be raised as grounds of invalidity in Canadian patent proceedings. A successful court-ordered correction — as occurred here — removes that specific invalidity vector going forward, since the register now reflects the court-confirmed inventor list. However, it may also invite scrutiny of the patents' broader prosecution and assignment history.
Both CA2645810 and CA3022097 are granted Canadian patents directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by an inhibitor of complement. PNH is a rare, life-threatening blood disorder caused by uncontrolled complement activation. Complement inhibitor biologics targeting this condition represent a high-value segment of the rare disease therapeutics market.
Yes. CA2645810 and CA3022097 are granted, enforceable Canadian patents in a high-commercial-value indication. The inventorship record has now been judicially confirmed, reducing one traditional challenge pathway. Any organisation developing complement inhibitor therapies for PNH with Canadian market exposure should conduct a formal freedom-to-operate analysis against both patents before advancing to late-stage development or commercialisation.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.